Recent News Stories Shows How The China Primary Hyperoxaluria (PH) Therapeutics Market Products Are Surviving In The Global Industry To 2028?

Report Overview

China Primary Hyperoxaluria (PH) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Primary hyperoxaluria (PH) is a group of rare genetic metabolic disorders that are characterized by the accumulation of a substance known as oxalate in the kidneys and other organ systems of the body. PH type I is the most common form. The global prevalence of PH type I is estimated to be 1-3 cases per 1,000,000 people. Globally PH1 accounts for 85% of patients, PH2 8-10% and PH3 5-7%. PH1 is the most severe form overall, more than 70% of PH1 patients develop end-stage kidney disease over time.

Market Drivers

China is a growing market for primary hyperoxaluria (PH) due to factors such as increase in global prevalence rate (1-3 cases per 1,000,000 people). In addition to this, other factors that contribute to the growth of market are rise in healthcare expenditure, increase in awareness and increase in R&D activities by private players.

However, there are some restraining factors for growth of primary hyperoxaluria (PH) therapeutics market in China such as undiagnosed or misdiagnosed, determining the true frequency of these conditions in the general population is difficult.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139818/

Major Players

Some of the key players in China's primary hyperoxaluria (PH) therapeutics market are Alnylam Pharmaceuticals Inc. Dicerna Pharmaceuticals Inc.

Dicerna received a rare paediatric disease designation from the U.S. Food and Drug Administration for Nedosiran for treatment of primary hyperoxaluria. Dicerna does not has its presence in China.

Alnylam Pharmaceuticals U.S. Food and Drug Administration (FDA) approval of Oxlumo (Lumasiran), the first and only treatment approved for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients. The company does not have its presence in China but it has other products which are approved in China. The Lumasiran drug is yet to be approved in China.

The China Primary Hyperoxaluria (PH) Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global China Primary Hyperoxaluria (PH) Therapeutics market. This report explores all the key factors affecting the growth of the global China Primary Hyperoxaluria (PH) Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On China Primary Hyperoxaluria (PH) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139818/

Market Segmentation

By Drug Type:

On the basis of drug type, the China primary hyperoxaluria (PH) therapeutics market can be segmented into Potassium Citrate, Thiazides, Magnesium, and Orthophosphates. These drugs are used along with the dietary supplementation such as Pyridoxine, also known as vitamin B6. Treatment may require the coordinated efforts of a team of specialists. Paediatricians, surgeons, specialists who assess and treat problems of the kidneys (nephrologists), specialists who assess and treat problems of the liver (hepatologists), specialists who assess and treat problems of the urinary tract (urologists).

By Therapy:

On the basis of therapy, the China primary hyperoxaluria (PH) therapeutics market can be segmented into cell therapy and gene therapy.

In gene therapy the defective gene present in a patient is either turned off and no longer able to function, as is the case with RNA interference, or is replaced with a normal gene to enable the production of the active enzyme and prevent the development and progression of the disease. These are investigational therapies.

By Distribution Channels:

On the basis of distribution channels, the China primary hyperoxaluria (PH) therapeutics market can be segmented into clinics, hospitals and others. During the forecast period (2020-2028) hospitals are the key distribution channels owing to the number of specialists required to diagnose and treat disease and easy availability of medicines in one place. In case of surgery the patients need to stay in the hospitals for 7 to 14 days. Clinics are the second largest distribution channels for the primary hyperoxaluria drug market due to which some of the patients may visit clinics for the treatment. Other distribution channels include retail and online pharmacies.

Major Players

Some of the key players in China's primary hyperoxaluria (PH) therapeutics market are Alnylam Pharmaceuticals Inc. Dicerna Pharmaceuticals Inc.

Dicerna received a rare paediatric disease designation from the U.S. Food and Drug Administration for Nedosiran for treatment of primary hyperoxaluria. Dicerna does not has its presence in China.

Alnylam Pharmaceuticals U.S. Food and Drug Administration (FDA) approval of Oxlumo (Lumasiran), the first and only treatment approved for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients. The company does not have its presence in China but it has other products which are approved in China. The Lumasiran drug is yet to be approved in China.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139818/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global China Primary Hyperoxaluria (PH) Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global China Primary Hyperoxaluria (PH) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Primary Hyperoxaluria (PH) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Primary Hyperoxaluria (PH) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Primary Hyperoxaluria (PH) Therapeutics
Chapter 4: Presenting the China Primary Hyperoxaluria (PH) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Primary Hyperoxaluria (PH) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139818/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the China Primary Hyperoxaluria (PH) Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.